Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Standards of Care II01:19

Standards of Care II

1.0K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.0K
Standards of Care I01:22

Standards of Care I

1.1K
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
1.1K
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

5.1K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
5.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

The journal of liquid biopsy·2026
Same author

Artificial Intelligence and the Evolving Paradigm of Lung Cancer Management.

Cancers·2026
Same author

STS Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-small Cell Lung Cancer.

The Annals of thoracic surgery·2026
Same author

Patient-derived three-dimensional lung tumor models to evaluate response to therapy.

NPJ precision oncology·2026
Same author

Sublobar Resection in Stage I Non-Small Cell Lung Cancer With Lymphovascular Invasion.

Annals of thoracic surgery short reports·2026
Same author

Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.

Biomolecules·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

The Evolving Clinical Utility of Gene Expression Profiling in Cutaneous Melanoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.

Gregory J Riely1, Douglas E Wood2, Dara L Aisner3

  • 11Memorial Sloan Kettering Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 10, 2025
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) were updated to focus on systemic therapy for nonmetastatic NSCLC. These updates include molecular testing recommendations for guiding treatment decisions.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

352
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Experiment Videos

Last Updated: Jan 18, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

352
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Area of Science:

  • Oncology
  • Clinical Guidelines

Background:

  • Non-Small Cell Lung Cancer (NSCLC) is a major cause of cancer-related mortality worldwide.
  • Current treatment strategies for NSCLC are evolving, necessitating updated clinical guidance.

Purpose of the Study:

  • To summarize recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC.
  • To highlight systemic therapy options for patients with nonmetastatic NSCLC.
  • To discuss molecular testing considerations relevant to these treatment updates.

Main Methods:

  • Review of the latest NCCN Guidelines for NSCLC.
  • Analysis of NCCN Guidelines Insights focusing on recent revisions.
  • Synthesis of information on systemic therapies and molecular testing for nonmetastatic NSCLC.

Main Results:

  • Recent NCCN Guidelines provide updated recommendations for systemic therapy in nonmetastatic NSCLC.
  • Specific molecular testing strategies are emphasized to inform treatment selection.
  • The guidelines address the integration of new therapeutic approaches into clinical practice.

Conclusions:

  • The updated NCCN Guidelines offer critical insights into managing nonmetastatic NSCLC.
  • Adherence to recommended systemic therapies and molecular testing can optimize patient outcomes.
  • These guidelines serve as an essential resource for oncologists treating NSCLC.